Vertex may have to pay more than $65 for Alpine Immune stock ($ALPN)

Group 1 - Alpine Immune Sciences Inc (NASDAQ: ALPN) shares increased by 35% following the announcement of its acquisition by Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) at a price of $65 per share [1][4] - The market capitalization of Alpine Immune is approximately $5.0 billion, and there is speculation that shareholders may receive more than the $65 per share due to an investigation launched by Halper Sadeh LLC into the acquisition agreement [2] - Year-to-date, Alpine Immune stock has more than tripled in value, indicating strong market performance [2] Group 2 - The acquisition is an all-cash transaction aimed at expanding Vertex Pharmaceuticals' presence in kidney disease treatment, expected to close by the end of the current quarter, subject to certain conditions [4] - Alpine Immune's recent financial results for the fourth quarter exceeded market expectations, although analysts at Morgan Stanley downgraded the stock to "equal weight" with a price target of $65, aligning with current trading levels [4]